Biocon Biologics completed the acquisition of the biosimilar assets of Viatris for $3.3bn.

Biocon Biologics, a biopharmaceutical company, completed the acquisition of the biosimilar assets of Viatris, an American global healthcare company, for $3.3bn. "This acquisition is transformational and will create a unique fully integrated, world leading biosimilars enterprise. Our long-standing global partnership with Viatris has enabled us to achieve many firsts, setting new benchmarks for the global biosimilars industry. This strategic combination brings together the complementary capabilities and strengths of both partners and prepares us for the next decade of value creation for all our stakeholders," Kiran Mazumdar-Shaw, Biocon Biologics Executive Chairperson.